[HTML][HTML] Neutralizing autoantibodies to type I interferons in COVID-19 convalescent donor plasma
SE Vazquez, P Bastard, K Kelly, A Gervais… - Journal of clinical …, 2021 - Springer
Journal of clinical immunology, 2021•Springer
Convalescent plasma has been a mainstay therapeutic in passive immunization for
decades. In the setting of the novel coronavirus (SARS-CoV-2), it has become widely used
for prophylaxis and early intervention in COVID-19 [1, 2]. Recently, neutralizing
autoantibodies to type I interferons have been described in at least 10% of patients with
critical COVID-19 pneumonia, while they were absent from infected individuals with
asymptomatic or mild disease [3]. These autoantibodies are likely pre-existing and have an …
decades. In the setting of the novel coronavirus (SARS-CoV-2), it has become widely used
for prophylaxis and early intervention in COVID-19 [1, 2]. Recently, neutralizing
autoantibodies to type I interferons have been described in at least 10% of patients with
critical COVID-19 pneumonia, while they were absent from infected individuals with
asymptomatic or mild disease [3]. These autoantibodies are likely pre-existing and have an …
Convalescent plasma has been a mainstay therapeutic in passive immunization for decades. In the setting of the novel coronavirus (SARS-CoV-2), it has become widely used for prophylaxis and early intervention in COVID-19 [1, 2]. Recently, neutralizing autoantibodies to type I interferons have been described in at least 10% of patients with critical COVID-19 pneumonia, while they were absent from infected individuals with asymptomatic or mild disease [3]. These autoantibodies are likely pre-existing and have an immunological impact early in the course of COVID-19 [3, 4].
Springer